^
Association details:
| Biomarker: | MSI-H/dMMR + PD-1 expression + CD8 positive |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Effective Response of Intrahepatic Cholangiocarcinoma to Pembrolizumab: A Case Report
Excerpt:
We began pembrolizumab treatment in a 69-year-old male with recurrent IHCCC at 18 months after his surgery because of the proven microsatellite instability (MSI)-high status. The patient had partial response...Intra-tumoral infiltration of both PD-1+ and CD8+ T cells may be a predictive factor of the efficacy of pembrolizumab.
DOI:
10.21873/anticanres.14411
